EAU 2017 | Recent developments in treatment options for castration-sensitive metastatic prostate cancer

Kurt Miller, MD, Phd, from Charité University Hospital, Berlin, Germany, discusses the combination of chemotherapy and hormone therapy at the European Association of Urology (EAU) conference in 2017 in London, UK. Treatment for hormone-sensitive metastatic prostate cancer used to involve androgen deprivation therapy, however a combination of chemotherapy and hormone therapy is now being used based on three recent studies; the GETUG study (NCT00104715) from France, the CHAARTED study (NCT00309985) from the US, and the STAMPEDE study (NCT00268476) from the UK. These studies all show that this combination confers a significant survival advantage. The STAMPEDE trial found a survival advantage of 22 months, the longest for any study on prostate cancer so far. This has been integrated into the EAU guidelines, and approximately 60-70% of patients now receive this treatment. There are still questions on whether every patient will benefit from this. The CHAARTED study has been re-evaluated, and it was determined that low volume disease patients do not have a survival advantage. The difference in number and location of metastases between low volume and high volume disease does not currently have a strict definition. He states that this is the only recent development in terms of treating metastatic disease.